IMPORTANCE Trial - A Provisional Study-design of a Single-center, Phase II, Double-blinded, Placebo-controlled, Randomized, 4-week Study to Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain
Latest Information Update: 25 Oct 2023
At a glance
- Drugs Esketamine (Primary)
- Indications Cancer pain
- Focus Therapeutic Use
- Acronyms IMPORTANCE
- 17 Oct 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 03 Mar 2022 Planned End Date changed from 1 Apr 2023 to 1 Apr 2024.
- 03 Mar 2022 Planned primary completion date changed from 1 Apr 2023 to 1 Apr 2024.